Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG

Leukemia and Lymphoma

Volumn 36, Issue 3-4, 2000, Pages 239-253

  Michiels, J J ^a,b   Barbui, T ^c   Finazzi, G ^c   Fuchtman, S M ^d   Kutti, J ^e   Rain, J D ^f   Silver, R T ^g   Tefferi, A ^h   Thiele, J ⁱ  

^a Goodheart Institute   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c OSPEDALI RIUNITI   (Italy)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f SAINT LOUIS HOSPITAL   (France)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h MAYO CLINIC   (United States)

ⁱ Erasmus Tower ^*

Author keywords

Clinical trials; Diagnosis; Polycythemia vera; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; HYDROXYUREA;

ACUTE LEUKEMIA; ARTICLE; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CELL MATURATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HEMATOCRIT; HISTOPATHOLOGY; HUMAN; IRON DEFICIENCY; MEGAKARYOCYTE; MEGALOCYTOSIS; MYELODYSPLASIA; MYELOFIBROSIS; MYELOID METAPLASIA; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTHEMIA; THROMBOCYTOPOIESIS; THROMBOSIS;

EID: 0033954268     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009148845     Document Type: Article

References (54)

1. Modan B. (1995) The epidemiology of polycythemia vera. In: Wasserman, Berk, Berlin: Polycythemia Vera and the Myeloproliferative Disorders. Chapter 12:140-146. W.B Saunders Company 1995. Philadelphia USA.
2. Chaiter Y, Brenner B, Aghai E, Tatarsky I. (1992) High incidence of myeloproliferative disorders in Ashkezi Jews in northern Israel. Leuk Lymph; 7:251-255.
3. Berglund S, Zettervall O. (1992) Incidence of polycythemia vera in a defined population. Eur J Haematol;48:20-26.
4. Dougan LE, Mathews MLV, Armstrong BK. (1981) The effect of diagnostic review on the estimated incidence of lymphatic and hematopoietic neoplasms in Western Australia. Cancer;48:866-872.
5. Carli PM. (1994) Epidemiology of polycythemia vera in Côte d'Or (Burgundy) Nouv Rev Fr Hematol;36:147-149.
6. Wasserman LR, Bassen F. Polycythemia. J Mount Sinai Hosp XXVI: 1-49, 1959.
7. Wasserman LR. (1954) Polycythemia vera, its course and treatment: relation to myeloid metaplasia and leukemia. Bull NY Acad Med: 30:343-375.
8. Wasserman LR, Berk PD, Berlin NI. (1995) Polycythemia vera and the myeloproliferative disorders. W.B. Saunders, Philadelphia. ISBN 0-7216-4213-6.
9. Berlin NI. (1975) The diagnosis and classification of the polycythemias. Semin Hematol;12:339-351.
10. Ellis JT, Peterson P. (1979) The bone marrow in polycythemia vera. Pathol Ann; 14: 383-403.
11. Ellis JT, Peterson P, Geller SA, Rappaport H. (1986) Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin. Hematol; 23:144-55.
12. Michiels JJ, Juvonen E. (1997) Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group (TVSG). Sem Thromb Hemostas; 23:339-346.
13. Michiels JJ and EWG.MPD. (1999) Diagnosis, pathogenesis and treatment of the myeloproliferative disorders. Neth J Med; 54:46-62.
14. Kurnick JE, Ward HP, Block MH. (1972) Bone marrow sections in the differential diagnosis of polycythemias. Arch Pathol; 94:489-499.
15. Georgii A, Vykoupil K-F, Buhr Th, Choritz H, Döhler U, Kaloutsi V, Werner M. (1990) Chronic myeloproliferative disorders in bone marrow biopsies. Path Res Pract; 186:3-27.
16. Georgii A, Buhr T, Buesche G, Kreft A, Choritz H. (1996) Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leukemia & Lymphoma; 22: suppl 1: 15-29.
17. Thiele J, Kvasnicka HM, Werden, C, Zankovich R, Diehl V, Fischer R. (1996) Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leukemia Lymphoma; 22: 303-317.
18. Thiele J, Kvasnicku HM, Diehl V, Fischer R., Michiels JJ. (1999) Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leukemia Lymphoma; 33:207-218.
19. Michiels JJ. (1997) Erythromelalgia and vascular complications in polycythemia vera. Sem Thromb Hemostas; 23:441-454.
20. Wetherley-Mein G. (1979) The course and complications of idiopathic erythrocytosis. Clin Lab Haematol; 1:189-196.
21. Najean Y, Triebel F, Dresch C. (1981) Pure erythrocytosis: Reappraisal of a study of 51 cases. Am J Hematol; 10:129-136.
22. Haanen C, Mathe G, Hayat M. (1981) Treatment of polycythemia vera by radiophophor or busulphan: a randomized trial. Br J Cancer; 44:75-80.
23. Berk PD, Goldberg JD, Donovan PB, et al. (1986) Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol: 23:132-143.
24. Kaplan ME, Mack K, Goldberg JD et al. (1986) Long-term management of polycythiemia vera with hydroxyurea: a progress report. Sem Hematol; 23:167-171.
25. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. (1997) From efficacy to safety: A Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. Sem Hematol; 34:17-23.
26. Barbui T, Finazzi G, de Gaetano G, Marchioli R, Tognoni G, Patrono C, Landolfi R. (1995) Gruppo Italiano Studio Policitemia. Polycythemia Vera: the natural history of 1213 patients followed for 20 years. Ann Int Med; 123:656-664.
27. Weitherley-Mein G. (1978) Vascular occlusive episodes and venous hematocrit in primary proliferative polycythemia. Lancet; 11:1219-1222.
28. Messinezy M, Prochazka A, Weitherley-Mein G. (1985) Treatment of primary proliferative polycythemia vera by venesection and low dose busulphan: retrospective study from one centre. Br J Haematol; 61:657-666.
29. Katarsky I, Sharon R. (1997) Management of polycythemia vera with hydroxyurea. Sem Hematol; 34:24-28.
30. Michiels JJ, Abels J, Steketee J, van Vliet HHDM, Vuzevski VD. (1985) Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Int Med; 102:466-471.
31. Frezzato M, Ruggeri M, Castamann G, Rodeghiero F. (1993) Polycythemia vera and essential thrombocythemia in young patients. Haematologica; 78:11:11-17.
32. Frohli P, Graf C, Rhyner K. (1983) Die Prophylaxe vascularer Komplikationen bei Polycythemia Vera und primarer Thrombozythämie mit niedrig dosierter Acetylsalicylsaure. Schweiz Med Wschr: 113:1622-1627.
33. Michiels JJ, Van Genderen PJJ, Lindemans J, Van Vliet HHDM (1996). Erythromelalgic, thrombolic and hemorrhagic manifestations in 50 cases of thrombocythemia. Leukemia & Lymphoma; 22:suppl 1:47-56.
34. Scheffer MG, Michiels JJ, Simoons ML, Roelandt JRTC. (1991) Thrombocythemia and coronary artery disease. Amer Heart J; 122:573-576.
35. Michiels JJ, Koudstaal PJ, Mulder AH, Van Vliet HHDM (1993). Transient neurological and ocular manifestations in primary thrombocythemia. Neurology: 43:1107-1110.
36. Van Genderen PJJ, Lucas IS, van Strik R, Vuzevski VD, Prins FJ, van Vliet HHDM, Michiels JJ. (1996) Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemostas; 76:333-338.
37. Van Genderen PJJ, Prins FJ, Michiels JJ, Schrör K. (1999) Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Brit J Haematol; 104:438-441.
38. Van de Petten JEW, Prochazka V, Singh A, Dickson ER, Wetherley-Mein G. (1986) Primary thrombocythemia treated with busulphan. Br J Haematol; 62:229-237.
39. Najean Y, Rain J-D, French PVSG. (1997) Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood; 90 3370-3377.
40. 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood; 89:2319-2327.
41. Silver RT. (1993) Interferon-alpha 2b: a new treatment for polycythemia vera. Ann Int Med; 119:1091-1092.
42. Silver RT. (1990) A new treatment for polycythemia vera: Recombinant interferon-alpha. Blood, 76:664-665.
43. Silver, RT. (1997) Interferon-alpha: Effects of long-term treatment for polycythemia vera. Sem Hem; 34: 40-50.
44. Taylor PC, Dolan G, Ng JP, et al. (1996) Efficacy of recombinant interferon-alpha in polycythemia vera: a study of 17 patients and an analysis of published data. Br. J. Haematol., 92:55-59.
45. Elliott MA, Tefferi A. (1997) Interferon-alpha in polycythemia vera and essential thrombocythemia. Sem Thromb Hemostas; 23:463-472.
46. Anagrelide Study Group. (1992) Anagrelide: a therapy for thrombocythemic states: experience in 577 patients. Am J Med; 92:69-76.
47. Tefferi A, Silverstein MN, Petitt RM, Meas RA, Solberg LA. (1997) Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications. Sem Thromb Hemostas; 23:379-383.
48. Petitt RM, Silverstein MN, Petrone ME. (1997) Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Sem Hematol; 34:51-54.
49. Solberg LA, Oles KJ, Tarah J, Silverstein MN, Petitt RM, Schracter L, Fleming J. (1989) The effects of anagrelide on human magakaryopoiesis. Blood; 74 (Suppl 1)20 (Abst).
50. Mazur EM, Rosmain AG, Sohl PA, Newton JL, Narendran A. (1992) Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood; 79:1931-1937.
51. Michiels JJ. (1999) Aspirin and platelet lowering agents for the prevention of vascular complications in essential thrombocythemia. Clin Applied Thromb Hemostas; 5:30-36.
52. Barbui T, Finazzi G. (1997) Risk factors and prevention of vascular complications in polycythemia vera. Sem Thromb Hemostas; 23:455-461.
53. Gruppo Italiano Studio Policitemia (GISP). (1997) Low-dose aspirin in polycythemia vera: a pilot study. Br J Haematol; 97:453-456.
54. Landolfi R, Marchioli R. (1997) European collaboration on low-dose aspirin in polycythemia vera (ECLAP): a randomized trial. Sem Thromb Hemostas; 23:473-488.